Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Lantheus Holdings (NQ: LNTH )

85.15 +1.07 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,791,080
Open 84.88
Bid (Size) 85.17 (11)
Ask (Size) 85.19 (3)
Prev. Close 84.08
Today's Range 83.31 - 85.38
52wk Range 50.20 - 126.89
Shares Outstanding 67,604,097
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:LNTH stands out as a stock that provides good value for the fundamentals it showcases.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH): good value for what you're paying. 
Via Chartmill
How Is The Market Feeling About Lantheus Holdings?
Via Benzinga

Performance

YTD
+34.94%
+34.94%
1 Month
-23.09%
-23.09%
3 Month
-11.91%
-11.91%
6 Month
+9.33%
+9.33%
1 Year
+31.85%
+31.85%

More News

Read More
After Trump's Win, It's Time To Take Profits On Gold
Via Benzinga
Topics Government
Exposures Political
Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
From Lantheus Holdings, Inc.
Via GlobeNewswire
Despite its growth, NASDAQ:LNTH remains within the realm of affordability.
Via Chartmill
Peering Into Lantheus Holdings's Recent Short Interest
Via Benzinga
NASDAQ:LNTH, a strong growth stock, setting up for a breakout.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Lantheus Reports Third Quarter 2024 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH, a strong growth stock, setting up for a breakout.
Via Chartmill
Why NASDAQ:LNTH Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:LNTH is not too expensive for the growth it is showing.
Via Chartmill
Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'
Via Benzinga
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
Via Chartmill
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH, an undervalued stock with good fundamentals.
Via Chartmill
NASDAQ:LNTH stands out as a growth opportunity that won't break the bank.
Via Chartmill
Bargain Hunting for Stocks: 2 Stocks to Buy in September
Via The Motley Fool
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Why NASDAQ:LNTH Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.